Form 4: Puma Biotechnology CFO Sells Shares

Puma Biotechnology's Chief Financial Officer, Maximo F. Nougues, reported the sale of 9,386 shares of common stock on July 6, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Maximo F. Nougues, Chief Financial Officer of Puma Biotechnology, Inc., sold 9,386 shares of common stock on July 6, 2026.
• The transaction was executed under a Rule 10b5-1(c) trading plan adopted on December 14, 2020.
• Following the transaction, Mr. Nougues beneficially owns 230,637 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling, despite the transaction being part of a pre-arranged plan.

Negatives

• The CFO sold a significant number of shares, which could be perceived negatively by the market.

Risks

• The sale of shares by a key executive could signal a lack of confidence in the company's future prospects, although it was conducted under a pre-existing trading plan.

Future Outlook

The filing does not contain forward-looking statements or guidance. The transaction was executed under a pre-existing trading plan.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes lead to increased investor scrutiny, particularly in the biotechnology sector where stock performance is often tied to clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders may view the CFO's sale of shares with caution, potentially impacting short-term stock sentiment, even though it was executed under a pre-established trading plan.

Key Dates

Keywords

Puma Biotechnology, PBYI, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Maximo F. Nougues, Chief Financial Officer